Anteris Technologies (AVR) Barclays 28th Annual Global Healthcare Conference summary

Key clinical and scientific insights

• DurAVR was developed with a total disease management approach, focusing on aortic stenosis beyond just device engineering, incorporating physician input and clinical science from the outset.

• The valve design is the first radical redesign in 20 years, addressing left ventricular remodeling and laminar flow, which are linked to improved outcomes and mortality.

• Extensive tissue science underpins the product, with over 10 years of published data showing no calcification in high-risk populations and superior performance compared to competitors.

• The biomimetic, single-piece, 3D-molded valve leverages unique acellular tissue properties, offering anti-calcific benefits and improved durability.

• Clinical data and podium presentations have demonstrated superior patient outcomes, driving strong physician and strategic interest.

Market strategy and competitive positioning

• The TAVR market is valued at $10 billion but has only 15% patient penetration, leaving significant untapped potential.

• The product is positioned as a rising star in the BCG matrix, with a proactive five-year pre-launch strategy involving key U.S. centers and clinical trials.

• Ease of use and clinical superiority are emphasized as differentiators, with a focus on addressing unmet needs in both physicians and patients.

• The company plans to justify a premium price through demonstrated clinical benefit and health economic modeling, aiming to extend patient mortality curves.

• Recent $300 million financing has reduced execution risk and supports ongoing development and commercialization.

Industry trends and future outlook

• The TAVR space is still evolving, with ongoing debates about patient selection, procedural settings, and the role of new technologies.

• Market growth is limited by factors such as diagnosis rates, procedural bottlenecks, and lack of earlier intervention incentives.

• Reimbursement trends are improving, with procedure-related payments increasing as length of stay decreases.

• The company is engaging heart failure specialists and promoting a polytherapeutic, multi-team approach to structural heart disease.

• Disease modification, such as left ventricular remodeling, is a key differentiator, with data showing significant improvements over six months.